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Abstract
Clinician dependent costs are the costs of care that are under the discretion of the healthcare provider. These
costs include the costs of drugs, tests and investigations, and discretionary outpatient visits and impatient stays.
The purpose of this review was to summarize recent evidence, relevant to both developed and developing
countries on whether evidence based clinical guidelines can change hospitals variable costs which are clinician
dependent, and the degree of financial savings achieved at hospital level. Potential studies for inclusion were
identified using structured searches of Econlit, J-Stor, and Pubmed databases. Two reviewers independently
evaluated retrieved studies for inclusion. The methodological quality of the selected articles was assessed using the
Oxford Centre for Evidence- Based Medicine (CEBM) levels of evidence. The results suggest that 10 of the 11
interventions were successful reducing financial costs. Most of the interventions, either in modeling studies or real
interventions generate significant financial saving, although the former reported higher savings because the studies
assumed 100 percent compliance.
Introduction
Globally, health care expenditures have increased tre-
mendously in the last decade raising concerns over their
sustainability[1-4]and value for money. This increased
investment is being made by both households and gov-
ernments and represents a potential pool of resources
that could be used elsewhere in the economy[2,4]. Such
an increase in expenditure if resulting in improved
health status would appear to be justified. However,
there are concerns that extra spending on health is not
yielding the anticipated health returns[1,5,6]. Therefore,
there is an increasing interest in maximizing the effi-
ciency of health care spending while at the same time
increasing the effectiveness of service provision. One
commonly used approach to improving the effectiveness
of health care is to develop guidelines for the health
care workers based on the best available evidence of
what works[7-9]. Often such guidelines aim to improve
outcomes through use of optimal treatment approaches
and to reduce or limit costs by therapies or procedures.
The degree to which guidelines work to change prac-
tices depends usually on the extent to which health
workers change their behaviour in response to the
guidelines as suggested in the Grimshaw 2004 review[7].
The cost consequence of such interventions has
received less attention in the literature. The degree to
which costs can be expected to change in response to
clinical guideline adoption will depend on both the
responsiveness of health worker behaviour, and on the
share of patient costs that are attributable to decisions
made by health workers. We have coined the term “clin-
ician-dependent costs”to describe the costs of care that
are under the discretion of the healthcare provider.
These costs include the costs of drugs, tests and investi-
gations, and discretionary outpatient visits and inpatient
stays. Changes in CDCs may arise from interventions
such as clinical guidelines that aim to alter health work-
ers use of available resources. We are therefore inter-
ested in examining the evidence that supports or refutes
the proposition that CDCs can be altered by interven-
tions aimed at changing health worker practices.
Methods
This review aimed to address the question of whether
and to what degree could interventions change costs
that are clinician dependent. The particular focus was
on studies reporting interventions designed to act
through clinicians’ behaviour change. We did not
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include studies describing the modeled difference in
costs of care after assuming one drug or combination of
drugs were substituted by an alternative drug or combi-
nation of drugs of equal or varying efficacy. Similarly we
did not include studies that reported the cost-difference
(or cost effectiveness difference) between alternative
drug regimens whose efficacy was being compared in
randomized controlled trials. Rather the focus was on
interventions that aimed at influencing the clinician to
follow a recommended process or procedure expected
to influence CDCs. In this case the effect on costs was
influenced by both the actual cost of the resources used
and the degree to which the clinician opts to follow the
advised procedures. Specifically this paper examines the
degree of financial savings attributed to the interven-
tions identified together with the resultant magnitude
expressed as the proportionate reduction in total or
consumable costs.
Potential studies for inclusion were identified by direct
searches of the online databases such as; PubMed, J-Stor
and Econlit and the grey literature to ensure a compre-
hensive literature review. The grey literature was sought
at several libraries including those of the Kenya Medical
Research Institute, Kenya Institute for Public Policy
Research and Analysis, Institute of Policy Analysis and
Research and the African Population and Health
Research Center, Searches were also conducted through
the websites of: The World bank, Department for Inter-
national Development, United States Agency for Interna-
tional Development, Policy Project- Kenya, Health Policy
Initiative and German Agency for Technical Co-opera-
tion (GTZ). Literature retrieved for the period 1995 to
2010 using the following combination of search terms:
■ Clinical guidelines and cost savings
■ Clinical prescribing behaviour and costs
■ Costs, decision making and prescribing variation
■ Prescription behaviour and costs
■ Prescribing behaviour and financial/costs savings
The titles and abstracts of the retrieved articles were
read by two independent reviewers and those that met
the pre-inclusion criteria were selected (Additional file
1, Tables S1 and S2). The methodological quality of the
selected articles describing interventions was assessed
using the Oxford Centre for Evidence Based Medicine
(CEBM) levels of evidence, which rank the validity of
evidence in a hierarchy of levels, with systematic reviews
as level 1 (strong evidence) and expert opinions as level
5 (weak evidence)[10] (Additional file 1, Table S3).
Results
The search terms used provided the following hits in
PubMed, J-Stor and Econlit. In total 874 titles were
screened, with 67 papers being reviewed. On reviewing
these articles only 16 were considered for this struc-
tured review because they were truly related to our
study question. The papers are described in Tables 1,
2 and 3 and in Additional file 1; Tables S1 and S2.
Four studies report on models reflecting the antici-
pated effects of an intervention only ("modeling stu-
dies”). Eleven report the results of true intervention
studies ("intervention studies”) we present and discuss
all of these studies.
Study context and design
This review included a total of 15 studies, 4 being mod-
eling studies and 11 being intervention studies. Interven-
tion studies included examined changes in CDCs after
implementation of an intervention aimed at changing
clinician prescribing behaviour and are the main focus
of this report. Study setting varied with 10 of 11 inter-
vention studies conducted in high income countries and
only one in low income setting[11]. All of the modeling
studies (4) were conducted in low income countries
[12-15] (see Table 1).
Table 1 Modeling studies
Reference/Design Country/
setting
Inclusion criteria/intervention Degree of financial saving LOE
Zurovac et-al. (2006);
Modeling study/
Secondary data[12]
Kenya Malaria microscopy is a potential solution to increase
diagnostic specificity and overcome the problem of
malaria over diagnosis
Costs of antimalarials decreased by 54% and
those antibiotics increased by 5%
5
Boulanger et-al. (1999);
Cross-sectional survey
[13]
Kenya IMCI guidelines would change drug prescribing
behaviour
Compliance with guidelines could have
reduced the cost of treatment by 42%
5
Kolstad et-al. (1998);
Cross-sectional survey
[14]
Uganda IMCI guidelines would change drug prescribing
behaviour
Use of IMCI could reduced costs of
medication to US$0.17 per child from US
$0.82 (A reduction of 80%)
5
Khan et-al. (2002);
Cross-sectional survey
[15]
Bangladesh IMCI guidelines would change drug prescribing
behaviour
Adoption of IMCI would reduce costs by
34%
5
LOE: Oxford Centre for evidence - Based Medicine level of evidence (May 2001)[10]
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The study designs of intervention studies included
comparative before and after studies[16-21], randomized
trials[11,22] a comparative study (with a non-random
allocation of study units)[23,24], and cluster randomized
trials[25,26]. Of these the randomized trials were
expected to provide the highest quality data with which
to answer the question posed. The modeling studies are
based on secondary data and all compared to theoretical
scenarios with or without a complete change of clinical
practice[12-15].
The level of evidence for economics and decision ana-
lysis as provided by the Oxford Centre for Evidence
Based Medicine is provided in Additional file 1, Table
S3. These criteria were used to evaluate the 11 interven-
tion studies that were included in this structured review.
A concise summary for both modeling and intervention
studies containing information on study design, setting,
intervention, the degree of financial saving attributed to
the intervention and level of evidence are provided in
Tables 1, 2 and 3 immediately after the main text.
Interventions
The interventions reported by studies included in this
structured review varied to a high degree although all
interventions aimed at, or modeled changes in clinician
behaviour through the use of clinical practice guidelines.
Interventions included: introduction of integrated
management of childhood illness (IMCI)[11] clinical
guidelines, a multifaceted intervention to improve pre-
ventive care delivered by nurses[24], a multidisciplinary
clinical pathway for oxygen management[22], a multifa-
ceted intervention to promote early switching from
intravenous to oral acetaminophen for post-operative
pain[17], introduction of new antibiotic protocols is the
treatment of pneumonia[19], an educational intervention
to decrease use of selected expensive medications[20],
use of clinical pathway designed to manage community
acquired pneumonia more efficiently than with conven-
tional therapy[25], use of commercially available pre-
scribing system with integrated clinical decision support
and evidence based message capability[23], clinical path-
ways for patients undergoing total laryngectomy[18],
inpatient diabetes management program[16] and evalua-
tion of educational outreach visits by community phar-
macists[26] on the effectiveness of guidelines. These
interventions aimed at changing clinician behaviour
either through training, prompts, feedback, supervision
or a combination of this process.
For example, the IMCI intervention study in Tanzania
involved an eleven day training period of which 30% of
the time was spent on clinical practice with one follow
up visit by an IMCI supervisor that occurred one month
after training. This intervention changed prescribing
behaviour which resulted in lower costs per child for the
total resources used in treatment but increased drug
costs[11]. In another study of a multifaceted intervention
Table 2 Intervention studies (Change in cost due to change in actual guidelines)
Reference/Design Country/
setting
Inclusion criteria/intervention Degree of financial saving LOE
Newton and Young
(2006); Before and after
study[16]
USA Inpatient diabetes management programme Reduction in length of stay for patients with
diabetes.
Has resulted in savings of more than $2 million
for the year and has yielded a 467% return on
investment
2b
McMullin et-al. (2005);
Intervention and control
[23]
USA Use of commercially available electronic
prescribing system with integrated clinical
decision support and evidence based message
capability
The proportion of prescriptions for high cost
drugs that were the target of this intervention to
prescribers was a relative 17.5% lower among the
intervention group compared with the control
group
2b
Wong et-at. (2000);
Intervention and control
[22]
Hamilton
Ontario
Multidisciplinary clinical pathway for oxygen
management
Total health system costs increased by 116% 2a
Hanna et-al. (1999); Before
and after study. Before
data was retrospective[18]
USA Use of a clinical pathway for patients
undergoing total laryngectomy
The average hospital variable cost decreased from
£3992 to £3419 per case. This represents a 14.4
reduction in costs associated with pathway
implementation
2b
Roth et-al (2001); Before
and after study[20]
USA Educational intervention to decrease use of
selected expensive medications
Annual saving of £66000 representing 32%
decrease in use of more costly anti- coagulant
and a 20% increase in the use of the less costly
anticoagulant
2b
Watson et-al. (2001);
Cluster randomized trial
[26]
Avon
England
Evaluate the effectiveness of guidelines with or
without one to one educational outreach visits
by community pharmacists
Mean costs reduced by 6% in practices that
received mailed guidelines and educational
outreach
1b
LOE: Oxford centre for Evidence-Based Medicine level of evidence (May 2001)[10]
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to improve preventive care delivered by nurses, the inter-
vention was in the form of training[24], which covered
an orientation session, medical office computer systems,
medical practice management, prevention in primary
care, evidence based medicine, and facilitator and audit
skills development. The intervention was more expensive
but more effective than any other attempts to modify pri-
mary care practice, since this intervention was targeted at
changing the entire practice and not just physician beha-
vior for a number of preventive measures and as a result
more time was spent on site and more visits were
required[24]. The study further suggests that the results
of this study suggests that the results of this study can be
considered an underestimate of the true potential costs
savings given that not all the costs associated with inap-
propriate and appropriate preventive care were consid-
ered. Moreover, this study was an efficacy trial and as a
consequence there is potential for reducing the cost of
the intervention through efficiency improvements such
as increasing the number of practices per facilitator as
well as savings in administration and training through
economies of scale. Another example comprises an inter-
vention included in the study on multidisciplinary clinical
pathway for oxygen management[22] which involved
teaching sessions and individualized audit and feedback
about oxygen ordering and monitoring. This intervention
changed prescribing and monitoring practices but
resulted in greater resource use, arguably improving the
quality of care, with individual audit and feedback pro-
vided by the research nurse being most instrumental in
achieving change[22]. The intervention on promoting
early switch from intravenous to oral acetaminophen for
postoperative pain included a local consensus process,
short educational presentation, posters displayed in all
nurses’ offices, and feedback of practices six months after
implementation of guidelines. This intervention leads to
a reduction in irrational prescriptions. The final example
of an intervention involved new antibiotic protocols
which recommended the use of amoxicillin or erythro-
mycin as a first line therapy for exacerbations of chronic
obstructive airways disease (COAD). The protocols were
effective because they resulted in significant reduction in
costs, attributed to a shorter duration of therapy.
The studies based on modeling behavior change cov-
ered topics including: adherence to a practice guideline
around malaria microscopy to overcome malaria over
diagnosis[12] and appropriate implementation of a set of
clinical practice guidelines in the form of the integrated
management of childhood illness (IMCI) approach
[13-15].
Effectiveness of interventions and Compliance with
guidelines
The success of any intervention aimed at altering clini-
cian prescribing depends on compliance which trans-
lates to the effectiveness in changing health worker
behavior. In a systematic review on effectiveness and
efficiency of guideline dissemination and implementa-
tion strategies, clinical guidelines were found to result in
observed improvements in care and absolute improve-
ments in performance[7]. However, although the review
reported significant effects of interventions the standar-
dized mean differences in practice from intervention to
control ranged from 0.9 to 6. This represents the magni-
tude of the change attributed to the intervention,
including information on statistical significance. A sum-
mary of interventions and standardized mean differences
is provided in Table 4 immediately after the main text
and the information is obtained from Grimshaw (2004)
[7]. In Table 4, standardized mean differences are not
provided in some of the columns because there was
insufficient data to facilitate its calculation.
Table 3 Intervention studies (Change in costs due to moving from incorrect to correct management)
Reference/Design Country/
setting
Inclusion criteria/intervention Degree of financial saving LOE
Adam et-al. (2005);
Comparative study[11]
Tanzania Districts with Integrated Management of
Childhood Illness (IMCI) against those without
Cost per child in IMCI district was 44% lower than
in district without IMCI. Although drug costs were
higher by 61% in IMCI districts
2b
Hogg et-al. (2005);
Randomized control trial[24]
Ontario
Canada
Multifaceted intervention to improve
preventive care delivered by nurses
Savings from a reduction in inappropriate testing
were 35% of total health system costs
1b
Ripouteau et-al. (2000); A
controlled prospective
before and after study[17]
France Multifaceted intervention to promote early
switch from acetaminophen for prospective
pain intravenous to oral
Mean cost per patient for analgesia decreased
from £14 to £6 after the intervention to a 57%
decrease
2a
Boyter et-al. (1995); Before
and after study[19]
Britain New antibiotic protocols, involving Amoxicillin
as a first line agent
Mean consumable cost per patient reduced
significantly from £14-09 to £10.20 this translates
to a 28% reduction
1b
Palmer et-al. (2000); Cluster
randomized Control trial[25]
Canada Use of a critical pathway designed to manage
community-acquired pneumonia more
efficiently than conventional therapy
The pathway produced cost savings of 16%, 24%
and 24% for the three perspectives respectively
1b
LOE: Oxford centre for Evidence-Based Medicine level of evidence (May 2001)[10]
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This review further evaluates the success of interven-
tions that are aimed at reducing clinician dependent
costs, and thus generate some financial savings to the
health system. On this note, interventions as opposed to
modeling studies will be considered because they did
not assume a high degree of compliance and they were
more pragmatic. However, 10 out of the 11 interven-
tions included in this review brought out the desired
effect (See Table 5: as suggested by the reported degree
of financial savings ranging from 6% to 57%). Only one
study did not report any savings, and further suggested
that multidisciplinary clinical pathway for oxygen man-
agement actually increased the costs of care by utilizing
more resources[27]. In addition, an important element
that deserves comment is the cost quality trade-off.
Effects on Costs
The effects of interventions on clinician dependent
costs, together with the cost areas forming the denomi-
nators, are presented in Table 5 immediately after the
main text. Several studies have reported the degree of
financial savings arising from certain interventions
aimed at improving clinicians’ prescribing behavior
[11-15,17,19,20,22,24-26]. The studies which modeled
the effect of changing health worker behavior present
degrees of financial savings on CDC’s limited to drug
costs ranging from 26 to 80 percent. On the other hand,
10 of 11 true interventions studies, whose denomina-
tions varied from total drug costs to total health systems
costs, reported financial savings ranging from 6 to 57
percent. Some studies don’t provide clear information
on whether they included intervention costs or not mak-
ing the analysis rather difficult as evident in Table 5.
However, in the study on a multidisciplinary clinical
pathway for oxygen management an increase in total
health systems costs by 116 percent[22] was reported
whereas in the study of IMCI in Tanzania although an
overall health system cost saving was reported this was
despite an increase in drug costs by 61 percent[11].
Discussion
In this section, prominent issues that surface from the
reviewed studies are discussed. The variation in the
denominator used in the costing approaches has clear
implications when interpreting the resultant degree of
financial saving. For example, financial savings presented
Table 4 Effects of clinical guidelines as provided by standardized mean differences
Intervention Source Standardized mean difference (intervention and
control)
Statistically
significant
Educational materials Randomized controlled trial + 0.25 Not Significant
Cluster allocated controlled clinical
trial
None Not applicable
Controlled before and after study +0.53 Significant
Educational Meetings Randomized controlled trial None Not applicable
Cluster allocated controlled clinical
trial
None Not applicable
Controlled before and after study None Not applicable
Audits and feedbacks Randomized controlled trial None Not applicable
Cluster allocated controlled clinical
trial
+0.2 CCT
Controlled before and after study None CBA
Reminders Randomized controlled trial -0.28 Not Ascertained
Cluster allocated controlled clinical
trial
None Not applicable
Controlled before and after study +0.15 Not Significant
Patient directed interventions Randomized controlled trial -0.67 Significant
Cluster allocated controlled clinical
trial
+6.00 Significant
Controlled before and after study +9.00 Significant
Other organizational
interventions
Randomized controlled trial +0.31 Significant
Cluster allocated controlled clinical
trial
None Not applicable
Controlled before and after study -0.21 Significant
RCT: Randomized controlled trial, CBA: Controlled before and after study, CCT: Cluster allocated controlled clinical trial.
Kosimbei et al. Health Research Policy and Systems 2011, 9:24
http://www.health-policy-systems.com/content/9/1/24
Page 5 of 8
Table 5 Degree of Financial savings
Interventions studies Degree of financial saving. {NB this is
overestimated for any other denominator
other than total health systems costs}
Proportion of total drug costs or total
health system costs
IMCI guidelines (Tanzania) Costs of drugs were higher by 61% compared to
control districts. Cost of the intervention not
included.
Total drug costs for managing outpatient
illness in those aged <5 years.
Health system costs per child were 44% lower in
intervention districts than in control districts. Cost
of the intervention was included.
Total health system costs (including start up
and post implementation costs) for
managing outpatient illness in those aged
<5 years.
Multidisciplinary clinical pathway for oxygen
administration
Led to changes in oxygen prescribing behaviour
but consumed more resources than standard
management by 116%. Cost of the intervention
was included.
Total health system costs (including start up
and post implementation costs).
Multifaceted intervention to improve
preventive care delivered by nurses
Costs decreased by 34%. Cost of the intervention
was included.
Total health system costs (training,
Supervision)
Use of commercially available electronic
prescribing system with integrated clinical
decision support and evidence - based
message capability.
The proportion of prescriptions for high costs
drugs that were the target of this intervention to
prescribers was a relative 17.5% lower among the
intervention group compared with the control
group.
Total drug costs
Multifaceted intervention to promote early
switch from intravenous to oral
acetaminophen for prospective pain
Costs decrease by 57%. Cost of the intervention
not included.
Total cost for acetaminophen analgesia costs
Clinical pathways for patients undergoing
total laryngectony
Hospital variable costs decreased by 14.4% Total hospital costs (both fixed and variable
costs)
New antibiotics protocol involving
amoxicillin as a first line agent.
Costs decrease by 28%. Cost of the intervention
not included.
Total antibiotics costs
Educational intervention to decrease use of
selected expensive medications
A 32% decrease in use of the more costly
anticoagulant and a 20% increase in use of the
less costly anticoagulant representing an
estimated annual savings of $66000. Cost of the
intervention not included.
Total anti-coagulant costs
Use of clinical pathway designed to manage
community acquired pneumonia more
efficiently than conventional therapy
Cost savings of 16%, 24% and 24% from the
perspectives: healthcare, government and societal.
Cost of the intervention not included.
Total consumable costs
Guidelines with one to one educational
outreach visits by community pharmacists
Mean costs reduce by 6%. Total drug costs including guideline
production and dissemination; together with
provision of education outreach visits
In patient diabetes management program The reduction in length of stay for patients with
diabetes has resulted in savings of more than $2
million for the year and has yielded a 467%
return on investment for the hospital.
Total hospital costs
Modeling studies Degree of financial saving Proportion of total drug costs or total
health system costs.
Malaria microscopy (change in clinical
practice)
Costs of prescribed Artemether-Lumefantrine
decreased by 54% while that of antibiotics
increased by 5%. Therefore, the overall drug cost
saving was 49%. Cost of the intervention not
included.
Total Outpatient drug costs
IMCI guidelines (Kenya) Cost of treatment reduced by an average of 42%.
Cost of the intervention not included.
Total drug costs for managing outpatient
illness in those aged <5 years
IMCI guidelines (Uganda) Cost of medication reduced by 80%. Cost of the
intervention not included.
Total drug costs for managing outpatient
illness in those aged <5 years
IMCI guidelines (Bangladesh) Cost of treatment reduced by 34%. Cost of the
intervention not included.
Total drug costs for managing outpatient
illness in those aged <5 years.
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as a percent of total drug costs may suggest a high
degree of success of the intervention. However, such
savings may be much less significant as financial savings
presented as a percent of total health systems costs. The
latter would obviously be preferred because it encom-
passes the total health system consequences as opposed
to dealing with only drug costs. Furthermore, total
health systems costs will include the marginal cost of
the intervention which has implications on the output.
We were able to identify only three of 8 studies that
included total health systems costs when reporting the
net savings. The variation in cost denominator used in
currently published work therefore makes it very hard
to compare or contrast different interventions and,
other than suggesting generally positive results in terms
of financial savings, limits the ability of current work to
inform policy more generally. In the particular case eval-
uating the introduction of IMCI guidelines the change
in perspective of the analysis, from direct resource cost
savings to total health system costs results in a comple-
tely different interpretation of the impact of the
intervention.
There are several determinants of cost savings which
are highlighted in the studies included in this review.
Some of these determinants are: minimizing laboratory
tests and procedures, increasing diagnostic specificity,
generic prescribing, use of cheaper and effective drugs,
and increasing local financial responsibility (with the
example of joining fund holding practices or primary
care groups in a developed country). However, several
issues stood out with respect to changing clinician
dependent costs.
The “room” or threshold to reduce costs
There is a possibility that studies are only conducted
and reported in areas where they already feel that costs
are unreasonably high[11,17,19,20,24,25], hence making
it more likely that their intervention will work. This bias
serves to show that clinical guidelines will always reduce
costs, whereas there are many other reasons why guide-
lines may be helpful in improving quality of care. It is
imperative that reduction of costs of financial savings
should not be the goal of an intervention, rather issues
such as quality of care.
The uptake of the clinical guidelines
Modeling studies assume a 100 percent success rate
whereas the intervention studies have a success rate of
less than 100 percent. This gives intervention studies
greater appeal for use in policy making because they use
real life scenarios. Furthermore, cost effectiveness stu-
dies of various interventions would be desired provided
quality of care is not disregarded. In this review, one
real intervention study evaluating the multidisciplinary
clinical pathway for oxygen management led to an
increase in health care costs, but improved the quality
of care significantly[22]. Besides, there is possibility that
studies are conducted for interventions that people
think will generate cost savings leading to the distinct
possibility of not only publication bias but research
initiation bias.
The cost quality trade-off
Minimization of costs through use of cheap or poor
quality resources may compromise health care quality.
An optimal balance is required based on cost effective-
ness of the particular intervention. It is necessary to
compare the costs of an intervention with the effective-
ness in order to justify resource use[28].
Conclusions
This review is aimed at establishing the degree of finan-
cial saving on clinician dependent costs brought about
by clinical guidelines. However, there was relatively little
specific literature on the cost consequences of
approaches to improving clinical practice despite the
broad literature exploring means to change clinician
behavior and improve practice. The methodological
quality of the selected articles was assessed using the
Oxford Centre for Evidence- Based Medicine (CEBM)
levels of evidence and in general the quality of studies
(summarized in Tables 1,2,3,5 and Additional file 1,
Tables S1 and S2) was reasonably high and included
several randomized controlled intervention trials. Eleven
of the twelve interventions were successful in that they
generated some financial savings (Table 5) however
there is a possibility of publication bias in this regard
plus the possibility that cost analyses are only underta-
ken if it can reasonably be expected that costs will be
reduced. Although studies that involved a purely model-
ing approach often suggested significant cost reductions,
they based these estimates on unrealistic assumptions of
compliance or health worker behavior change and are
consequently assigned a low level of evidence. These
studies are likely to overestimate potential savings
(Table 3). This drawback could be addressed by con-
ducting sensitivity analysis with different compliance
rates and emphasizing that the results are based on
modeling assumptions closest to observed degrees of
practice change.
Additional material
Additional File 1: Table S1. Levels of evidence for economic and
decision analysis as provided by the Oxford Centre for Evidence- Based
Medicine Table S2 Summary of studies included in the systematic
review (Real interventions) Table S3 Summary of studies included in the
systematic review (Modeling studies).
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